45 results
6-K
EX-99.3
ENLV
Enlivex Therapeutics Ltd
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
significant survival benefits when Allocetra™ is combined with PD1 or CTLA4 checkpoint inhibition, respectively
Appointed new Vice Chairman of the Board … models of ovarian cancer, in collaboration with the Yale Cancer Center, and mesothelioma, showed substantial, synergistic survival benefits when
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
31 Mar 23
Report of Foreign Private Issuer
4:30pm
of interest, expected dividend yield, expected volatility and the expected life of the award.
Employee benefits
The Company is required by Israeli law … a number of post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
10 Feb 15
Notice of Extraordinary General Meeting of Shareholders
12:00am
(the “Plan”).
Benefits
The Executive will be entitled to participate in all benefit plans made available to global chief executive officers of other … -rata bonus, full payment of six months healthcare benefits to the Executive’s dependents and right to exercise vested options for a year after the death
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
31 May 22
Report of Foreign Private Issuer
8:04am
immunotherapeutic effects and its potential to deliver survival benefits across multiple solid cancers when combined with various immune checkpoint inhibitors … . The immunosuppressive microenvironments of ovarian tumors have limited the clinical benefits of checkpoint inhibition in this indication. Allocetra™ may reverse
6-K
EX-99.1
fbrtah00go9 uj
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
6-K
EX-99.1
79p7es1 lyrz6rob
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.4
wau7qar9eao
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.1
s1309abg
19 Feb 19
Asset Purchase Agreement
4:57pm
6-K
h1jxim
24 Oct 19
Current report (foreign)
8:00am
6-K
EX-99.1
vv9frodf
5 Oct 22
Notice of Annual General Meeting of Shareholders
3:00pm
6-K
odmqf3rw 8h
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.1
q4tv01kkn
6 Jun 22
Report of Foreign Private Issuer
8:03am
20-F/A
ztetnh qou
23 Jan 20
Annual report (foreign) (amended)
4:31pm